在现实生活中，无论之前是否使用过生物药物以及是否存在关节受累情况，替拉珠单抗治疗中重度银屑病均显示出良好疗效。 - Suppr | 超能文献

相似文献

1

Tildrakizumab in real-life shows good efficacy in moderate-to-severe psoriasis regardless of previous use of biologic drugs and joint involvement.在现实生活中，无论之前是否使用过生物药物以及是否存在关节受累情况，替拉珠单抗治疗中重度银屑病均显示出良好疗效。

Dermatol Ther. 2022 Nov;35(11):e15818. doi: 10.1111/dth.15818. Epub 2022 Sep 22.

2

Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.老年银屑病患者的抗白细胞介素-23 治疗：真实世界中 Guselkumab、Risankizumab 和 Tildrakizumab 的应用。

Clin Exp Dermatol. 2022 Mar;47(3):561-567. doi: 10.1111/ced.14979. Epub 2021 Nov 17.

3

Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study.替拉珠单抗治疗中重度斑块状银屑病：一项多中心、回顾性、真实世界研究。

Dermatol Ther. 2022 Jun;35(6):e15488. doi: 10.1111/dth.15488. Epub 2022 Apr 11.

4

Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden.替西罗莫司：一种针对高体重或高疾病负担的中重度斑块状银屑病患者的个性化、灵活治疗方法的价值。

Expert Opin Biol Ther. 2024 Mar;24(3):133-138. doi: 10.1080/14712598.2024.2325547. Epub 2024 Mar 5.

5

Effectiveness and safety of tildrakizumab in individuals with HIV and psoriasis: A case series.替拉珠单抗治疗 HIV 合并银屑病患者的疗效和安全性：一项病例系列研究。

Int J STD AIDS. 2024 Nov;35(13):1084-1086. doi: 10.1177/09564624241279489. Epub 2024 Sep 3.

6

Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1).替西罗莫司单抗治疗中度至重度斑块状银屑病日本患者的疗效和安全性：一项 64 周 3 期研究（reSURFACE 1）的结果。

J Dermatol. 2021 Jun;48(6):853-863. doi: 10.1111/1346-8138.15789. Epub 2021 Feb 25.

7

Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate-to-severe chronic plaque psoriasis.在一项2b期和两项3期试验中，根据患者人口统计学和疾病特征评估替拉珠单抗治疗中重度慢性斑块状银屑病的疗效。

J Eur Acad Dermatol Venereol. 2020 Jul;34(7):1500-1509. doi: 10.1111/jdv.16187. Epub 2020 Feb 9.

8

Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2).替西罗莫司治疗银屑病的疗效、药物存活率和安全性在合并和不合并代谢综合征的患者中相当：来自 2 项 3 期随机对照研究（reSURFACE 1 和 reSURFACE 2）的长期结果。

J Am Acad Dermatol. 2021 Feb;84(2):398-407. doi: 10.1016/j.jaad.2020.09.047. Epub 2020 Sep 19.

9

Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients with Moderate-to-Severe Plaque Psoriasis.古塞库单抗在中重度斑块状银屑病患者中的免疫原性不具有临床相关性。

J Invest Dermatol. 2019 Aug;139(8):1830-1834.e6. doi: 10.1016/j.jid.2019.02.018. Epub 2019 Mar 6.

10

Tildrakizumab for the treatment of moderate to severe psoriasis: Results from a single center preliminary real-life study.替拉珠单抗治疗中度至重度银屑病：一项单中心初步真实世界研究的结果

Dermatol Ther. 2022 Dec;35(12):e15941. doi: 10.1111/dth.15941. Epub 2022 Oct 19.

引用本文的文献

1

Optimizing Psoriasis Treatment with Tildrakizumab: Current Evidence and Expert Recommendations for Treatment Individualization in Clinical Practice.使用替拉珠单抗优化银屑病治疗：临床实践中治疗个体化的当前证据和专家建议

Dermatol Ther (Heidelb). 2025 Sep 11. doi: 10.1007/s13555-025-01538-4.

2

Effectiveness and Safety of Tildrakizumab in Elderly and Frail Elderly Psoriatic Patients Up to 2 years.替拉珠单抗治疗老年及体弱老年银屑病患者长达2年的有效性和安全性

Psoriasis (Auckl). 2025 Aug 4;15:339-350. doi: 10.2147/PTT.S525256. eCollection 2025.

3

Real-World Study of Tildrakizumab Survival in Psoriasis: Impact of Arthritis, Hypertension, and Prior Biologic Use.